Cargando…

An evaluation of risk-based monitoring in pragmatic trials in UK Clinical Trials Units

BACKGROUND: Good Clinical Practice guidelines issued in 2016 encourage risk-based approaches to monitoring clinical trials. This study compared current risk assessment and monitoring approaches in UK Clinical Trials Units (CTUs) with the published guidance and makes recommendations for risk-based mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Beever, Daniel, Swaby, Lizzie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734501/
https://www.ncbi.nlm.nih.gov/pubmed/31500656
http://dx.doi.org/10.1186/s13063-019-3619-6
_version_ 1783450164316340224
author Beever, Daniel
Swaby, Lizzie
author_facet Beever, Daniel
Swaby, Lizzie
author_sort Beever, Daniel
collection PubMed
description BACKGROUND: Good Clinical Practice guidelines issued in 2016 encourage risk-based approaches to monitoring clinical trials. This study compared current risk assessment and monitoring approaches in UK Clinical Trials Units (CTUs) with the published guidance and makes recommendations for risk-based monitoring in pragmatic trials. METHODS: An online survey of UK Clinical Research Collaboration registered CTUs was administered via email invitation. Forty-nine units were invited, and 23 responded. Respondents were also invited to share copies of risk assessment templates. RESULTS: Most CTUs reported using remote combined with on-site monitoring. All reported undertaking a risk assessment for Clinical Trials of Investigational Medicinal Products (CTIMPs) and 21 units did so for non-CTIMPs. Most CTIMP risk assessments used MHRA (Medicines and Healthcare products Regulatory Agency) classifications, although some also employed staff judgement. Almost all units based their monitoring on perceived risk level; this number was higher for CTIMPs (n = 22) than for non-CTIMPs (n = 19). In most cases, monitoring plans were produced. More CTUs revisited risk assessments during trials in CTIMPs (n = 21) than in non-CTIMPs (n = 18). Small numbers of units reviewed the monitoring approach always (n = 4) or sometimes (n = 9) and few used the reflection to guide future monitoring. CONCLUSIONS: A high proportion of UK CTUs are using risk-based monitoring in the UK, as recommended by guidelines, for both CTIMPs and non-CTIMPs. This has the potential to make trials more efficient and reduce costs. However, there appears to be a lack of reflection on the value of these revised approaches. There may be a benefit in CTUs collaborating nationally to improve processes for reflection and making changes during the life course of a trial. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13063-019-3619-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6734501
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-67345012019-09-12 An evaluation of risk-based monitoring in pragmatic trials in UK Clinical Trials Units Beever, Daniel Swaby, Lizzie Trials Research BACKGROUND: Good Clinical Practice guidelines issued in 2016 encourage risk-based approaches to monitoring clinical trials. This study compared current risk assessment and monitoring approaches in UK Clinical Trials Units (CTUs) with the published guidance and makes recommendations for risk-based monitoring in pragmatic trials. METHODS: An online survey of UK Clinical Research Collaboration registered CTUs was administered via email invitation. Forty-nine units were invited, and 23 responded. Respondents were also invited to share copies of risk assessment templates. RESULTS: Most CTUs reported using remote combined with on-site monitoring. All reported undertaking a risk assessment for Clinical Trials of Investigational Medicinal Products (CTIMPs) and 21 units did so for non-CTIMPs. Most CTIMP risk assessments used MHRA (Medicines and Healthcare products Regulatory Agency) classifications, although some also employed staff judgement. Almost all units based their monitoring on perceived risk level; this number was higher for CTIMPs (n = 22) than for non-CTIMPs (n = 19). In most cases, monitoring plans were produced. More CTUs revisited risk assessments during trials in CTIMPs (n = 21) than in non-CTIMPs (n = 18). Small numbers of units reviewed the monitoring approach always (n = 4) or sometimes (n = 9) and few used the reflection to guide future monitoring. CONCLUSIONS: A high proportion of UK CTUs are using risk-based monitoring in the UK, as recommended by guidelines, for both CTIMPs and non-CTIMPs. This has the potential to make trials more efficient and reduce costs. However, there appears to be a lack of reflection on the value of these revised approaches. There may be a benefit in CTUs collaborating nationally to improve processes for reflection and making changes during the life course of a trial. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13063-019-3619-6) contains supplementary material, which is available to authorized users. BioMed Central 2019-09-10 /pmc/articles/PMC6734501/ /pubmed/31500656 http://dx.doi.org/10.1186/s13063-019-3619-6 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Beever, Daniel
Swaby, Lizzie
An evaluation of risk-based monitoring in pragmatic trials in UK Clinical Trials Units
title An evaluation of risk-based monitoring in pragmatic trials in UK Clinical Trials Units
title_full An evaluation of risk-based monitoring in pragmatic trials in UK Clinical Trials Units
title_fullStr An evaluation of risk-based monitoring in pragmatic trials in UK Clinical Trials Units
title_full_unstemmed An evaluation of risk-based monitoring in pragmatic trials in UK Clinical Trials Units
title_short An evaluation of risk-based monitoring in pragmatic trials in UK Clinical Trials Units
title_sort evaluation of risk-based monitoring in pragmatic trials in uk clinical trials units
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734501/
https://www.ncbi.nlm.nih.gov/pubmed/31500656
http://dx.doi.org/10.1186/s13063-019-3619-6
work_keys_str_mv AT beeverdaniel anevaluationofriskbasedmonitoringinpragmatictrialsinukclinicaltrialsunits
AT swabylizzie anevaluationofriskbasedmonitoringinpragmatictrialsinukclinicaltrialsunits
AT beeverdaniel evaluationofriskbasedmonitoringinpragmatictrialsinukclinicaltrialsunits
AT swabylizzie evaluationofriskbasedmonitoringinpragmatictrialsinukclinicaltrialsunits